Association Between Toxic Effects and Survival in Patients With Cancer and Autoimmune Disease Treated With Checkpoint Inhibitor Immunotherapy

Catherine Young Han; Conall Fitzgerald; Mark Lee; Cristina Valero; Mithat Gönen; Alexander Shoushtari; Luc G T Morris

doi:10.1001/jamaoncol.2022.2081

Association Between Toxic Effects and Survival in Patients With Cancer and Autoimmune Disease Treated With Checkpoint Inhibitor Immunotherapy

JAMA Oncol. 2022 Sep 1;8(9):1352-1354. doi: 10.1001/jamaoncol.2022.2081.

Authors

Catherine Young Han¹, Conall Fitzgerald¹, Mark Lee¹, Cristina Valero¹, Mithat Gönen², Alexander Shoushtari³, Luc G T Morris¹

Affiliations

¹ Immunogenomics and Precision Oncology Platform, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
² Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
³ Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Abstract

This cohort study analyzed the safety and efficacy of immune checkpoint inhibitors in patients with cancer and autoimmune disease, and examined whether immune-related toxic effects were associated with outcomes.

Publication types

Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural

MeSH terms

Autoimmune Diseases* / etiology
Humans
Immunotherapy / adverse effects
Neoplasms*

Grants and funding

P30 CA008748/CA/NCI NIH HHS/United States